Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 706 of 6351
-
New hope for gallbladder cancer: chemo plus immunotherapy combo tested
Disease control Recruiting nowThis phase II trail will evaluate the efficacy and safety of combining gemcitabine hydrochloride, cisplatin, nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation), with durvalumab in treating patients who have locally advanced or metastatic gallbladder cancer. …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for Hard-to-Treat prostate cancer: RS-113 under study
Disease control OngoingThe primary objective of the study is to determine the therapeutic dose of RS-113 in patients with metastatic castration-resistant prostate cancer based on efficacy, safety, and pharmacokinetic parameters. The secondary objectives are to assess a pilot efficacy and safety of diff…
Phase 2 • Sponsor: R-Pharm International, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for sickle cell patients: drug aims to cut painful crises
Disease control Recruiting nowA phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occ…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Experimental injection aims to boost Chemo's punch in aggressive breast cancer
Disease control Recruiting nowAbout 10-20% of all individuals with breast cancer have a so-called triple-negative tumor (TNBC). This type of breast cancer has a particularly unfavorable course and a higher mortality rate compared to other forms of breast cancer. Research studies show that it is important for …
Phase 2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a new drug DM001 take on advanced solid tumors?
Disease control OngoingThe goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM001 for patients with the advanced solid tumors. DM001 is an experimental drug which is not approved by health authorities for the treatment of advanced solid tumors. Participants wi…
Phase 1 • Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Blood test could replace risky needle for prenatal genetic diagnosis
Diagnosis Recruiting nowCell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in maternal plasma. Its presence in maternal plasma has allowed development of noninvasive prenatal diagnos…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New hope for pancreatic cancer: EXPAND trial targets limited metastases
Disease control Recruiting nowThe EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
Phase 3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug mosunetuzumab takes on standard therapy in lymphoma trial
Disease control Recruiting nowThis phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and s…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Experimental CART123 therapy targets tough blood cancers in early trial
Disease control Recruiting nowAdult patients with refractory or relapsed CD123+ hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, or blastic plasmocytoid dentritic cell neoplasm will be recruited in the trial. CART123 cells will be manufatured …
Early phase 1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for kidney patients: targeted drug may replace harsh chemotherapy
Disease control Recruiting nowThis is a randomized, parallel group, active-controlled, open-label, Phase III study comparing the efficacy and safety of obinutuzumab versus cyclophosphamide combined with glucocorticoids in patients with primary membranous nephropathy (pMN). Approximately 144 patients with pMN …
Phase 3 • Sponsor: Huashan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug duo aims to tackle tough lymphoma
Disease control Recruiting nowThis is a Phase 2, multicenter study evaluating the efficacy and safety of mosunetuzumab + zanubrutinib (M+Z) used as salvage strategy in patients with R/R FL who have received at least one line of prior systemic therapy.
Phase 2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New smart drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered JK06 in patients with unresectable locally, advanced or metastatic cancer.
Phase 1/2 • Sponsor: Salubris Biotherapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Can a higher dose of adenosine sharpen heart scans?
Disease control Recruiting nowAdenosine is a commonly used pharmaceutical stressor at cardiac magnetic resonance examinations to assess suspected chronic coronary syndrome (CCS). However, several studies have reported that the current use of adenosine does not induce adequate hyperemic response in a substanti…
Phase 4 • Sponsor: Region Skane • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a simple oxygen device prevent breathing trouble in obese patients during endoscopy?
Disease control CompletedObese patients often have fat accumulation in the head and neck, increased soft tissue in the oropharynx, decreased lung compliance, decreased lung volume and residual volume, and some obese patients also suffer from obstructive sleep apnea. Therefore, obese patients may experien…
Sponsor: XiaoLiang Wang • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New antibody combo tackles tough leukemia
Disease control Recruiting nowThe planned trial offers treatment cohorts for patients with full cytologic relapse (R/R ALL - Cohort 1), as well as for patients with molecular failure/relapse (MRD+ ALL - Cohort 2). Basically, the study aims to develop data for optimization of first-line therapy of T-ALL, eithe…
Phase 2 • Sponsor: Goethe University • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can cannabis compounds help tame opioid cravings and chronic pain?
Symptom relief Recruiting nowThe primary objective of this phase 2 study is to investigate the therapeutic potential of orally administered combined delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in relieving both pain and cue-induced opioid craving in people with co-occurring opioid use disorder (…
Phase 2 • Sponsor: Yale University • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
New hope for kids with rare blood vessel disease: avacopan trial launches
Disease control OngoingThe main objective of this study is to explore the efficacy of avacopan in participants affected by AAV.
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo aims to stall prostate cancer spread
Disease control Recruiting nowThis study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New daily pill could ease sleep apnea for those with excess weight
Disease control OngoingStudy GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have modera…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hope for advanced prostate cancer: drug combo trial launches
Disease control Recruiting nowDespite improvements in treatment, metastatic prostate cancer remains incurable, especially in the case of pretreated metastatic castration-resistant disease (mCRPC), where treatment options are limited, leading to an unmet need. The paradigm shift in the treatment of metastatic …
Phase 2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC